OverviewSuggest Edit

ImmVira is a company that develops biopharmaceutical technology in the field of immunotherapy. The company provides medical solutions to treat cancer and tumor. It offers a product called Oncolytic Herpes Simplex Virus that aims to eliminate metastatic tumors or tumors inaccessible by direct injection.
TypePrivate
Founded2015
HQShenzhen Shi, CN
Websiteimmvira-theravir.com

Latest Updates

Employees (est.) (Apr 2022)11(-8%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at ImmVira

Grace Zhou

Grace Zhou

CEO/CSO
Bernard Roizman

Bernard Roizman

Chair of BOD
Show more

ImmVira Office Locations

ImmVira has an office in Shenzhen Shi
Shenzhen Shi, CN (HQ)
1301 Guanguang Rd, Longhua Qu
Show all (1)

ImmVira Financials and Metrics

Summary Metrics

Founding Date

2015

ImmVira total Funding

$90.5 m

ImmVira latest funding size

$10 m

Time since last funding

2 years ago

ImmVira investors

ImmVira's latest funding round in September 2020 was reported to be $10 m. In total, ImmVira has raised $90.5 m
Show all financial metrics

ImmVira Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

ImmVira Online and Social Media Presence

Embed Graph

ImmVira News and Updates

ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials

SHENZHEN, China, July 18, 2021 /PRNewswire/ -- On July 18, 2021, ImmVira inaugurated a pilot-scale production line in Shenzhen and officially initiated its in-house production of our next-generation oncolytic viruses (OV) used for IND applications and Phase I/II clinical trials....

ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China

SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in both China and the U.S. on May 28 2021 and June...

ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021

SHENZHEN, China, June 2, 2021 /PRNewswire/ -- ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021 for the first time. MVR-T3011 is ImmVira's...

ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting

SHENZHEN, China, April 8, 2021 /PRNewswire/ -- ImmVira today announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8 2021. Results from the first Phase 1 study of MVR-T3011...

ImmVira Announces Series C Financing with Leading Specialist Investors

SHENZHEN, China, Dec. 31, 2020 /PRNewswire/ -- ImmVira Group Company ("the Company"), a biotechnology platform dedicated to the development of oncolytic virus("OV") and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of...

Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer

SHENZHEN, China, June 30, 2020 /PRNewswire/ -- Today Immvira Group Company (Immvira or the "Company"), a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, announces the appointment of Carl Yeung as Chief Financial...
Show more

ImmVira Frequently Asked Questions

  • When was ImmVira founded?

    ImmVira was founded in 2015.

  • Who are ImmVira key executives?

    ImmVira's key executives are Grace Zhou and Bernard Roizman.

  • How many employees does ImmVira have?

    ImmVira has 11 employees.

  • Who are ImmVira competitors?

    Competitors of ImmVira include ImmunSYS, Precision Medicines and Plus Therapeutics.

  • Where is ImmVira headquarters?

    ImmVira headquarters is located at 1301 Guanguang Rd, Longhua Qu, Shenzhen Shi.

  • Where are ImmVira offices?

    ImmVira has an office in Shenzhen Shi.

  • How many offices does ImmVira have?

    ImmVira has 1 office.